Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin. 1993

A M van den Besselaar, and J Neuteboom, and R M Bertina
Department of Haematology, Leiden University Hospital, The Netherlands.

The activated partial thromboplastin time (aPTT) is the most popular test for monitoring of heparin therapy. The purpose of the present study was to show that an aPTT reagent with good response to heparin can be prepared from synthetic phosphoglycerides. Mixed liposomes were prepared from synthetic dioleoylphosphatidylserine (DOPS), dioleoylphosphatidylcholine (DOPC), and dioleoylphosphatidylethanolamine (DOPE). These liposomes were used in an aPTT test system with kaolin as activator, to evaluate their procoagulant activity in the absence and presence of heparin. For comparison, mixtures of purified non-synthetic phospholipids were prepared and tested with the same systems. The aPTT and its response to heparin were influenced by the phospholipid class composition and concentration. The presence of phosphatidylserine (PS) was required to reduce the aPTT of normal plasma to values between 30 and 40s. The presence of phosphatidylethanolamine (PE) in mixed liposomes could modulate the response to heparin. At low PE/PS liposome concentrations (approximately 40 microM), a relatively low response was observed. At high liposome concentrations (approximately 1 mM), the response to heparin increased with the mole fraction of phosphatidylethanolamine. The results obtained with non-synthetic phospholipid mixtures were similar to those obtained with the synthetic phosphoglycerides. Optimal concentrations of DOPS, DOPE and DOPC were found with which an almost linear response to heparin and to low molecular weight heparin (Fragmin) was observed. Using a mixed liposome consisting of 12 microM DOPS/12 microM DOPC/16 microM DOPE, a doubling of the base-line aPTT was achieved at approximately 0.2 IU/ml of heparin, and at approximately 1.0 IU/ml of Fragmin.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D010713 Phosphatidylcholines Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety. Choline Phosphoglycerides,Choline Glycerophospholipids,Phosphatidyl Choline,Phosphatidyl Cholines,Phosphatidylcholine,Choline, Phosphatidyl,Cholines, Phosphatidyl,Glycerophospholipids, Choline,Phosphoglycerides, Choline
D010714 Phosphatidylethanolamines Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to an ethanolamine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and ethanolamine and 2 moles of fatty acids. Cephalin,Cephalins,Ethanolamine Phosphoglyceride,Ethanolamine Phosphoglycerides,Ethanolamineglycerophospholipids,Phosphoglyceride, Ethanolamine,Phosphoglycerides, Ethanolamine
D010718 Phosphatidylserines Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a SERINE moiety. Serine Phosphoglycerides,Phosphatidyl Serine,Phosphatidyl Serines,Phosphatidylserine,Phosphoglycerides, Serine,Serine, Phosphatidyl,Serines, Phosphatidyl
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005227 Fatty Acids Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed) Aliphatic Acid,Esterified Fatty Acid,Fatty Acid,Fatty Acids, Esterified,Fatty Acids, Saturated,Saturated Fatty Acid,Aliphatic Acids,Acid, Aliphatic,Acid, Esterified Fatty,Acid, Saturated Fatty,Esterified Fatty Acids,Fatty Acid, Esterified,Fatty Acid, Saturated,Saturated Fatty Acids
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017985 Dalteparin A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed) Tedelparin,Dalteparin Sodium,FR-860,Fragmin,Fragmine,Kabi-2165,FR 860,FR860,Kabi 2165,Kabi2165,Sodium, Dalteparin

Related Publications

A M van den Besselaar, and J Neuteboom, and R M Bertina
September 1978, American journal of clinical pathology,
A M van den Besselaar, and J Neuteboom, and R M Bertina
February 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
A M van den Besselaar, and J Neuteboom, and R M Bertina
April 1979, American journal of clinical pathology,
A M van den Besselaar, and J Neuteboom, and R M Bertina
October 1972, American journal of clinical pathology,
A M van den Besselaar, and J Neuteboom, and R M Bertina
November 1975, American journal of clinical pathology,
A M van den Besselaar, and J Neuteboom, and R M Bertina
June 1998, Archives of internal medicine,
A M van den Besselaar, and J Neuteboom, and R M Bertina
May 1977, American journal of clinical pathology,
A M van den Besselaar, and J Neuteboom, and R M Bertina
May 1998, Archives of internal medicine,
A M van den Besselaar, and J Neuteboom, and R M Bertina
November 1995, Thrombosis and haemostasis,
A M van den Besselaar, and J Neuteboom, and R M Bertina
March 1971, Canadian Medical Association journal,
Copied contents to your clipboard!